Collegium Pharmaceutical Completes Series A Financing from Boston Millennia Partners.Business Editors CUMBERLAND, R.I.--(BUSINESS WIRE)--Oct. 28, 2003 Collegium col·le·gi·um n. pl. col·le·gi·a or col·le·gi·ums 1. An executive council or committee of equally empowered members, especially one supervising an industry, commissariat, or other organization in the Soviet Union. Pharmaceutical, Inc., privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products announced today that it has completed its Series A financing with venture capital firm, Boston Millennia Partners. The investment marks Collegium's first round of institutional capital. With over 80 products developed over the past 30 years, the Years, The the seven decades of Eleanor Pargiter’s life. [Br. Lit.: Benét, 1109] See : Time Collegium management team has a proven track record of taking products from lab to market. Jane Hirsh, Collegium's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , was the founder and CEO of Copley Pharmaceuticals, which was acquired by TEVA TEVA Tucson Electric Vehicle Association Pharmaceuticals. Collegium has established an extensive patent portfolio for late stage products that it plans to bring to market over the next three years. Collegium has forged collaborations and in-licensing agreements with a number of large pharmaceutical companies and academic institutions. "Millennia is delighted to partner with Collegium's impressive management team and assist in bringing their products to market. We have known the founders for many years. They are proven industry professionals who have built meaningful companies in the past. We look forward to playing an active role in the company's growth," said Dana Callow, Managing General Partner. Patrick Fortune, PhD, Partner will join the Board of Collegium. "The Company's platform of a great technology team, experienced management and strong intellectual property, combined with solid business partnerships, creates a great opportunity for both fast growth and strong operating performance," said Dr. Fortune. "This financing will accelerate the development of several late stage pharmaceutical products poised to enter the market in the coming three years," said Michael Heffernan Michael Heffernan (3 April, 1885 – 21 November, 1970) was an Irish Farmers' Party politician. He was first elected to Dáil Éireann in 1927 as a TD for Tipperary. He served as Parliamentary Secretary to the Minister for Posts and Telegraphs from 1927 to 1932. , Collegium's President. "We are very pleased to have Boston Millennia as a partner. This funding will allow Collegium to establish the critical capacity necessary to move our products forward and enter into discussions with potential partners. Having someone with Pat Fortune's operating background and senior executive experience in companies like Monsanto, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were and Baxter International will be a particular advantage as we scale up our business." About Collegium Pharmaceutical, Inc. Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. The Company's products target market opportunities through product improvement and line extension strategies protected by intellectual property (IP), creating a portfolio of improved pharmaceutical products. Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see ), marketing and clinical trials management to identify and execute product opportunities across multiple therapeutic areas. For more information, visit the Company's website at www.collegiumpharma.com. About Boston Millennia Partners Boston Millennia Partners is a private equity investment partnership managing over $700 million in capital. From its office in Boston, Millennia invests in high-growth businesses in the healthcare and life sciences, information technology and business services, and telecommunications industries. Typical investments range from $3 to $15 million. The managers at Millennia have funded over 120 companies in the U.S. private equity market since 1980. Portfolio companies with whom they have invested include PAREXEL International (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : PRXL), ILEX Ilex a bush bearing berries containing saponins; cause vomiting, diarrhea. Called also holly. Oncology (NASDAQ: ILXO), Verio (NASDAQ: VRIO VRIO Virtual Reality Input Output ), Proteome/Incyte Genomics (NASDAQ:INCY), and HotJobs/Yahoo (NASDAQ: YHOO YHOO Yahoo! Inc. (NASDAQ symbol) ), among others. For more information, visit our website at www.millenniapartners.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion